Korea:207940

Frost & Sullivan Institute Recognizes Samsung Biologics with the 2022 Global Enlightened Growth Leadership Award for its Commitment to Sustainable Growth

Samsung Biologics' mission to create a better world through high-quality biopharmaceuticals is underscored by a series of global initiatives to deliver progress related to climate change SAN ANTONIO, Aug. 9, 2022 /PRNewswire/ -- Frost & Sullivan Institute is proud to present Samsung Biologics wi...

2022-08-09 21:17 2565

GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine

* GreenLight's messenger RNA production process is transferable to large-scale equipment and CMO facilities * Technology transfer and scale-up from lab bench to Samsung's commercial facility was completed in seven months * GreenLight's mRNA synthesis reaction had a titer of 12g/L at a commer...

2022-08-01 21:00 2255

Samsung Biologics Reports Second Quarter 2022 Financial Results

* Released consolidated financial position of the company based on its full acquisition of Samsung Bioepis completed onApril 20, 2022 * Achieved record-high semi-annual revenue exceeding KRW 1 trillion * Recorded Q2'22 revenue of KRW 503.7 billion for the company's CDMO business * Recorded ...

2022-07-27 14:43 1936

Samsung Biologics to purchase land for its second Bio Campus

* Acquires additional land, sized 357,366㎡ valued at KRW 426 billion, for Bio Campus 2 * Plans to build Multi-Modal Plant, Open Innovation, and expanded manufacturing capacities INCHEON, South Korea, July 18, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contrac...

2022-07-18 19:00 1591

'Sustainable CDMO' Samsung Biologics releases 2022 ESG Report

* Aims to build an eco-friendly business environment and achieve net zero GHG emissions in its operations, moving towards 100% renewable energy. * Details new social contribution activities that strives to support the health of its local communities. * Requires commitment to the Supplier Cod...

2022-07-11 19:00 1972

Samsung Biologics Reports First Quarter 2022 Financial Results

* Q1'22 revenue of KRW 511.3 billion increased 96% compared to Q1'21. * Q1'22 operating profit of KRW 176.4 billion increased 137% compared to Q1'21. * Stable business operations and utilization rates across Plants 1, 2, and 3. * Proactive investments into long-term growth, capacity, and su...

2022-04-27 14:42 1772

Samsung Biologics completes full acquisition of Samsung Bioepis

* Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary * First payment completed funded through paid-in capital * Accelerated growth expected in biosimilars and future novel therapeutics R&D INCHEON,South Korea, April 20, 2022  /PRNewswire/ -- Samsung Biologi...

2022-04-20 14:45 1918

Samsung Biologics holds 11th Annual General Meeting of Shareholders

INCHEON, South Korea, March 28, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), hosted its 11th Annual General Meeting of Shareholders (AGM)today. Five matters were presented and approved unanimously at this ...

2022-03-29 09:42 1916

Samsung Biologics receives 2022 CMO Leadership Award in all six categories

INCHEON, South Korea, Feb. 7, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), announced that it has been selected as a winner of the 2022 CMO Leadership Awards presented by Outsourced Pharma and Life Science ...

2022-02-07 20:00 1966

Samsung Biologics reaches agreement with Biogen to acquire full ownership of Samsung Bioepis

* Agreement with Biogen to buyout Biogen's (50% -1 share) stake in Samsung Bioepis Joint Venture for up to USD$2.3 billion * Transaction projected to be accretive to earnings in 2022 and thereafter, fully capitalizing on the high growth potential of Samsung Bioepis * Expected to accelerate g...

2022-01-28 08:10 1823

Samsung Biologics Reports Fourth Quarter & Fiscal Year 2021 Financial Results

* Q4'21 revenue of KRW 444.3 billion increased 18% compared to Q4'20. * Q4'21 operating profit of KRW 128.8 billion increased 39% compared to Q4'20. * FY'21 revenue of KRW 1,568.0 billion, an increase of 35% compared to FY'20. * FY'21 operating profit of KRW 537.3 billion, an increase of 84% ...

2022-01-24 16:25 1973

Samsung Biologics Shares Strategic Roadmap for Sustainable Growth at the 40th Annual JP Morgan Healthcare Conference

INCHEON, South Korea, Jan. 12, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced its sustainable growth plan for this year at the 2022 Annual JP Morgan Healthcare Conference, which is held virtually fromJanuary 10th to 13th with leaders from major pharmaceutical and biopharmaceuti...

2022-01-13 08:52 1902

Moderna COVID-19 Vaccine Manufactured in Korea by Samsung Biologics Receives Marketing Authorization from Ministry of Food and Drug Safety of Korea

CAMBRIDGE, Mass. and INCHEON, South Korea, Dec. 14, 2021 /PRNewswire/ -- Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced today that the Ministry of Food and Drug Safety of Korea (MFDS) has issued a marketing authorization for Sp...

2021-12-14 13:34 1557

Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy

INCHEON, South Korea, Dec. 13, 2021 /PRNewswire/ -- Samsung Biologics (207940.KS), the world's leading contract development and manufacturing organization, continues its strategic biopharmaceutical manufacturing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN). The partnership is based on an...

2021-12-14 08:55 1674

Samsung Biologics adds to global ISO certifications with Quality Management System

* Samsung Biologics earns ISO9001 for Quality Management System, proving its capabilities to ensure high-quality service offerings throughout a product life-cycle * The company is fully certified with the recognition across all of its CDO, CMO and all other core business units in Plant 1,2, a...

2021-12-07 13:04 1612

GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity for messenger RNA Vaccine Manufacturing

BOSTON and INCHEON, South Korea, Nov. 24, 2021 /PRNewswire/ -- GreenLight Biosciences (Nasdaq: ENVI), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, and Environmental Impact Acquisition Corp, and Samsung Biol...

2021-11-24 20:00 1910

Samsung Biologics Reports Third Quarter 2021 Financial Results

* Q3'21 revenue of KRW 450.7 billion increased 64% compared to Q3'20. * Q3'21 operating profit of KRW 167.4 billion increased 196% compared to Q3'20. * Stable supply, strong operational excellence and a high utilization rate across all plants. * Active investment on expansion, pre-sales ac...

2021-10-26 15:23 1647

Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA

INCHEON, South Korea, Sept. 22, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (CDMO), introduced its proprietary technology platform, S-CellerateTM, at the BioProcess International Conference (BPI 2021) to offer clients an integrated and seam...

2021-09-22 18:00 1453

Samsung Biologics Joins Frontier 1.5D Project as part of 2050 Carbon Neutral Initiative

INCHEON, South Korea, Sept. 13, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, announced the signing of an MOU today to participate in the Frontier 1.5D initiative to develop a climate risk management model as part...

2021-09-13 12:41 1484

Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody Immunotherapy

* Kineta to leverage Samsung Biologics' development and manufacturing expertise to advance KVA12.1 to IND * Samsung Biologics San Francisco R&D center and South Korea headquarters to offer a seamless, end-to-end CDMO service INCHEON, South Korea and SEATTLE, July 20, 2021 /PRNewswire/ -- Sams...

2021-07-20 20:00 1429
12345